OVID News and Press, Ovid Therapeutics Inc. From 05/07/19

Remains on track for all previously stated milestones expected throughout 2019 The STARS study selected as one of three abstracts featured at the 2019 AAN Top Science Press Conference NEW YORK, May 07, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceuti...

Gainers:  Aquantia (NYSE: AQ ) +36% . Sinclair Broadcast (NASDAQ: SBGI ) +28% . Athenex (NASDAQ: ATNX ) +25% . Bridgeline Digital (NASDAQ: BLIN ) +22% . Regulus Therapeutics (NASDAQ: RGLS ) +18% . Ovid Therapeutics (NASDAQ: OVID ) +17% . Daxor Corporation (NYSEMKT: DXR ) +17% ....

Aquantia (NYSE: AQ ) +36%  on $452M sale to Marvell. More news on: Aquantia Corp., Ovid Therapeutics Inc., Adaptimmune Therapeutics plc, Stocks on the move, Read more ...

Ovid Therapeutics (NASDAQ: OVID ) is up  16%  premarket on robust volume on the heels of two presentations  at the American Academy of Neurology Annual Meeting in Philadelphia on lead candidate OV101. More news on: Ovid Therapeutics Inc., Healthcare stocks news, Stocks on t...

Noteworthy events during the latter part of the week of April 28 - May 4 for healthcare investors. More news on: UroGen Pharma Ltd., ESSA Pharma Inc., EyePoint Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

Emerging Science platform presentation highlights efficacy and safety data of OV101 in Angelman syndrome from the STARS study  Research from Ovid’s Fragile X program shows new insights for outcome assessments NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therape...

Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Firm news: Andreessen Horowitz plans to become a registered investment advisor in a shift away from venture capital...

ADMA Biologics (NASDAQ: ADMA ) +46%  as FDA approves ADMA Biologics' ASCENIV. More news on: ADMA Biologics, Inc., Sangamo Therapeutics, Inc., Riot Blockchain, Inc., Stocks on the move, Read more ...

Ovid Therapeutics (NASDAQ: OVID ) announces changes to its senior management team to focus the company’s resources and attention on its late stage pipeline. More news on: Ovid Therapeutics Inc., Healthcare stocks news, Read more ...

NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced changes to its senior management team to focus the company&#...